Target
Procarbazine
3 abstracts
Abstract
Survival outcomes associated with first-line PCV or temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma.Org: Paris Brain Institute (ICM), Service de Neurologie 2 Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, AP-HP, Sorbonne Université, Lyon HCL,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).Org: Institut Curie, Saint Cloud, France, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière,